Display options
Cite
Florian AR, Cruciat G, Pop RM, et al. Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus. Exp Ther Med. 2021;21(5):520doi: 10.3892/etm.2021.9951.
Florian, A. R., Cruciat, G., Pop, R. M., Staicu, A., Daniel, M., & Florin, S. (2021). Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus. Experimental and therapeutic medicine, 21(5), 520. https://doi.org/10.3892/etm.2021.9951
Florian, Andreea Roxana, et al. "Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus." Experimental and therapeutic medicine vol. 21,5 (2021): 520. doi: https://doi.org/10.3892/etm.2021.9951
Florian AR, Cruciat G, Pop RM, Staicu A, Daniel M, Florin S. Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus. Exp Ther Med. 2021 May;21(5):520. doi: 10.3892/etm.2021.9951. Epub 2021 Mar 22. PMID: 33815593; PMCID: PMC8014980.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2021 May;21(5):520. doi: 10.3892/etm.2021.9951. Epub 2021 Mar 22.

Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus.

Experimental and therapeutic medicine

Andreea Roxana Florian, Gheorghe Cruciat, Raluca Maria Pop, Adelina Staicu, Muresan Daniel, Stamatian Florin

Affiliations

  1. Obstetrics and Gynecology I, Mother and Child Department, 'Iuliu Ha?ieganu' University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
  2. Department of Pharmacology, Toxicology and Clinical Pharmacology, 'Iuliu Ha?ieganu' University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.

PMID: 33815593 PMCID: PMC8014980 DOI: 10.3892/etm.2021.9951

Abstract

Gestational diabetes mellitus (GDM) is one of the most common complications of pregnancy, leading to considerable maternal and fetal risks. The main aim of this study was to determine the predictive value of the levels of adiponectin (AN), leptin (L) and CMPF (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) in the development of GDM. We conducted a prospective longitudinal study on 68 pregnant women that were not at risk of developing GDM, in whom we determined AN, L, CMPF levels at 11-13 weeks +6 days of pregnancy during the first trimester screening. Twenty-one of all the patients included in the study developed GDM during pregnancy. Oral glucose tolerance test (OGTT)/75 g was performed at 24-28 weeks of gestation. L levels were significantly higher in patients who developed GDM than in those who did not develop diabetes (P<0.001). The AN/L ratio was significantly lower in patients with GDM (P=0.03). AN and CMPF levels were not associated with GDM. The probability of developing gestational diabetes was higher in patients with L levels above the L cut-off value of 16 ng/ml [area under the curve (AUC), 0.775; 95% confidence interval (CI) 0.658-0.867], sensitivity 100% (95% CI 83.9-100), specificity 48.9% (95% CI 34.1-63.9) (P<0.001). Advanced maternal age and higher L levels were found to be predictive factors [odds ratio (OR)=1.16 and OR=1.06, respectively] independently associated with gestational diabetes. In as far as general factors are concerned, the patient BMI (body mass index) at the beginning of the pregnancy and smoking were found to be the main risk factors for the onset of GDM. This study showed that elevated L levels are a strong predictor of GDM, while AN and CMPF levels are not, as they failed to show a significant association.

Copyright: © Florian et al.

Keywords: CMPF; adipokines; adiponectin; adiponectin/leptin ratio; gestational diabetes mellitus; leptin

Conflict of interest statement

The authors declare that they have no competing interests.

References

  1. J Int Med Res. 2013 Feb;41(1):123-8 - PubMed
  2. Clin Sci (Lond). 2002 Aug;103(2):137-42 - PubMed
  3. Int J Obes (Lond). 2011 Feb;35(2):226-35 - PubMed
  4. PLoS Med. 2007 Oct 16;4(10):e296 - PubMed
  5. Gynecol Endocrinol. 2010 Jul;26(7):539-45 - PubMed
  6. Diabetes Care. 2010 Mar;33(3):676-82 - PubMed
  7. Diabetes Care. 2016 Jan;39 Suppl 1:S4-5 - PubMed
  8. Clin Nutr Res. 2017 Oct;6(4):267-276 - PubMed
  9. J Proteome Res. 2011 Aug 5;10(8):3732-42 - PubMed
  10. Clin Endocrinol (Oxf). 2008 Sep;69(3):407-11 - PubMed
  11. Diabetes Care. 2014;37(5):1296-303 - PubMed
  12. Diabetes. 2010 Dec;59(12):3017-22 - PubMed
  13. Eur J Clin Nutr. 2013 Feb;67(2):196-201 - PubMed
  14. Br J Nutr. 2010 Jan;103(1):50-7 - PubMed
  15. Diabetes Care. 2013 Jun;36(6):1577-83 - PubMed
  16. Obstet Gynecol. 2004 Mar;103(3):519-25 - PubMed
  17. Prenat Diagn. 2011 May;31(5):479-83 - PubMed
  18. Diabetol Metab Syndr. 2016 Sep 13;8(1):68 - PubMed
  19. Clin Chem Lab Med. 2017 Oct 26;55(11):1805-1812 - PubMed
  20. Obesity (Silver Spring). 2011 Feb;19(2):416-21 - PubMed
  21. Diabetes Care. 2012 Mar;35(3):526-8 - PubMed
  22. PLoS One. 2015 Apr 15;10(4):e0124379 - PubMed
  23. J Clin Endocrinol Metab. 2012 Nov;97(11):4148-55 - PubMed
  24. Arch Med Res. 2011 May;42(4):318-23 - PubMed
  25. Cell Metab. 2014 Apr 1;19(4):653-66 - PubMed
  26. Cell Metab. 2014 Apr 1;19(4):553-4 - PubMed
  27. Metabolism. 2015 Jun;64(6):756-64 - PubMed
  28. Lipids Health Dis. 2020 Jan 4;19(1):2 - PubMed
  29. Taiwan J Obstet Gynecol. 2011 Jun;50(2):149-53 - PubMed
  30. Exp Ther Med. 2019 Jul;18(1):685-691 - PubMed
  31. Birth Defects Res C Embryo Today. 2015 Mar;105(1):53-72 - PubMed

Publication Types